Diabetes and Glycemic Monitoring: in Southern Regions The Challenge is to enhance the use of New Technologies

Diabetes by Many is referred to as “The Chronic Disease” Because Its Management Impact is trully Representative of an all-Round Complex Chronicity. The current pandemic has brought to light all the weaknesses in the care system, very much related in particular to territorial care taking. Campania, As Well As Other Regions, Sicily, Calabria and Puglia Are Facing the “Diabetes Emergency”.

Availability of and Access to Technologies, Still Uneven from Region to Region, is a Key Issue in Taking Care of the Diabetic Patient as they have Been Shown to Improve Glycemic Control by Reducing Hospitalizations and Management Costs. TODAY, A DIABETIC PATIENT COSTS ABOUT 3.500 Euros to the National Health System, Where Hospitalizations Absorb About 60 percent. Investing in Innovation would Thus Ensure A Paradigm Shift in the Value-Based Management of People With Diabetes In Line With The Goals Of The Nrp, While Also Reducing Management Costs by About 1.600 Euros for Year for Patient, As for An Analysis conducted in the Tuscany Region on the Use of the FGM System.

The New National Recovery and Resilience Plan

The New National Recovery and Resilience Plan Allocates € 15.63 Billion (€ 7 Billion Bethaeen Outreach Networks, Facilities, TeleMedicine Services and € 8.63 Billion on Innovation, Research, Digitalization). But the Innovation Produced by Drugs and Devices in Italy, Has a Fair and Uniform Access Comparable to That of Other European Countries? And in Italy, Regions Offer at Uniform Landscape About Access? What opportunities will the nrp Provide, How Will It Be Declined In Different Regions, And Will It Be Able To Meet The Needs Of People With Diabetes?

The Planned Organizational Change Will Be Able To Ensure Easier Access To Innovation and Care Pathways by Simplifying Care Taking and Monitoring? Will Focus On Education and Empowerment of the person with diabetes?

Just During the Event “Pnrr and Diabetes“, with a focus on the south, organized by Healthcare Engine With the Unconditional Contribution of Abbott and Boehringer Ingelheim, Southern Regions Have VoiceD Their Experiences and Proposals for Improving Care on the Ground Thus Taking Care of the Diabetic Patient.

Diabetes Represents The Leading Cause of Blindness

Diabetes is the leading Cause of Blindness, The Leading Cause of NonTraumatic Lower Limb Amputation, The Second Leading Cause of Terminal Renal Failure Up to dialysis or Transplantation, The Contribution Cause of Half of All Heart Attacks and Strokes. In Italy, According to the National Epidemiological Bulletin of the Higher Institute of Healthy Waut Be about 3.4-4 Million People With Diabetes But About 1-1.5 Million Who Do Not Know These Have It, While 4 Million People would at high risk of development the disease. According to the Most Recent Estimates, The diabetes spending Bethaeen Direct Health Care Costs (About 9 Billion) and Indirect Health Care Costs (About 11 Billion) would currently love to at least 20 billion euros for Year. These numbers give insight Into soci-medical and health-economic impact.

An Important Step Has Recently Been Taken by the Italian Society of Diabetology (SID) and By the Association Physicians Diabetologists (AMD) Who Novenced That they have Developed a Position Paper For the definition of a New Model of Diabetes Management to Be Implemented with the Resources Allocated by the PNRR in Which Community Medicine, Thus Chronic Noncommunicable Diseases, Represent One of the FundaMental Focuses.

Pasquale Cananzi, Head of Pharmacy Regional Center Pharmacovigilance and Vaccinovigilance of the Sicilian Region, Highlighted the Issue of Diabetes, Described As “Strategic” for the Sicilian Region, Which Wants To Be There at this time of Change in the Management of Diabetic Disease.

“The Sicily Region Wants To Take Up the Challenge of Innovation. The new Note 100 revolutionizes the paradigm of care from a pharmaceutical and territorial point of view because it turns, it moves toward: a deprescription of therapies unanimously considered obsolete, I am talking about sulfonylureas; an increasingly widespread access to new therapies with direct prescription to General Medicine, an access procedure that the Region of Sicily, always with a view to a timely opening to innovation, has made its own by eliminating the passage from the Regional Commission making Sicily from an Aifa determination of authorization of a new drug provides for its availability on the territory within about twenty days. We consider these to be important and almedady concrete aspects of making innovations available.

Blood Glucose Control Devices Clearly Fall Under This Type of Evaluation Because There is a Full Undersanding That They Contribute Significantly to Improving The Performance of the Patient’s Glycemic Control, and Almedy in Sicily It is a Pathway Started in Patienti Initialy with Type 1 Diabetes and Now Also In patients with insulin-dependent type 2 diabetes.”.

In Campania, The Change is Underway

“In The Campania Region WEV Have World Numbers of Diabetes, in Terms of Both prevalence and complications, and they are Also World in Terms of the Incident of Childhood Diabetes (Type 1 Diabetes), But Campania Has Managed to make important steps, IT HAS Taken Change of All Diabetic Children and it is doing the same with regard to adult diabetes (375 thousand cases, 7 percent of the population, and by 2035 there will be 600 thousand)he explained Peter Good, Head of UOD Consulting and Maternal and Child Health Activities Campania Region, which counts 61 Anti-diabetes centers, amounting to one center for 3-4 thousand patients with diabetes. “At the regional referral centers, we have done close training in the use of new blood glucose monitoring technologies because we believe they are an added value in that they improve the quality of life of patients, so they must be implemented in the use appropriately with the aim of increasing the number of people who benefit from them. Technologies are an objective resource on which we are making a targeted bid with the goal of freeing up resources to ensure that more people use pumps and sensors.”.

Another aspect highlighted by Dr. Good was prevention and the training. “We need to work better on prevention because there is no facility in the world that can follow so many patients with diabetes. Finally, we need to do more recruiting and more training of health personnel to address this health emergency.”.